Let us celebrate Make In India, we have a well-earned reason for that…

image

Let us celebrate Make In India, we have a well-earned reason for that…

We are referring to celebration tagged to Wipro-GE healthcare’s recent accomplishment of CT system launch. This system costs less than 40% of traditional available CT systems in market, and addresses everything that you ever wished for from cost and quality perspective.

While half of country was debating around “Make In India campaign’s” success or failure, Milan Rao, CEO and President of GE Healthcare South Asia & his dynamic team was busy leveraging technical know-how and skill set that country India beholds.

Wipro-GE team thought through this execution so well, that even before the product was launched the company had right distribution and training channel laid out across the country.

Some of the must know features of the CT system include

  • 36 per cent lower radiation with a smart dose.
  • 28 per cent lower life cycle cost
  • Half the weight of a traditional machine.

This all round approach of Wipro-GE joint venture is commendable and only deserves applaud, we wish more companies materialize on their Make In India beliefs.

For now let us all celebrate and cherish the vision, and soon to become reality of Affordable healthcare.

Kudos to Milan Rao and his team for making us believe that right treatment is available at reasonable price.

For More Medtech Updates : Follow Medical Device Trends

Medical Device Trends

Advertisements

India’s new development on device pricing-Boon or Bane for Make In India?

amin20111001112037123

India has been most watched emerging market for medical devices. Country houses right infrastructure, technical know-how, not to forget regulatory knowledge in comparison to all its peer nation involving China, Thailand, Taiwan, Malaysia and others.

The cherry on cake was PM Modi’s recent Make in India campaign which provides incentives to foreign manufacturers to manufacture in India and levy government support on tax and other reforms. Further, last year’s government eased policy to allow 100% FDI under the automatic route in this sector made the situation more favourable for Indian medtech industry.

Country houses right infrastructure, technical know-how, not to forget regulatory knowledge in comparison to all its peer nation involving China, Thailand, Taiwan, Malaysia and others.

This streamlined flow of activities witnessed a sudden break when government raised a concern demanding medical devices price capping. The authorities wanted essential medical devices that are flagged to critical care, to have their price contained in order to make the devices affordable for patients across country.

Teams flagged to the process are likely to sit on the same, and come to the conclusion of how they will balance patients and manufacturers expectation. While one requests for affordability other looks for making cash in order to promote innovation.

Governing bodies are stuck in dilemma, root cause of which comes from the fact seeded to price disparity between indigenous and foreign brands.Foreign manufacturers respond to this by putting the quality difference reason as explanation to higher price quotes.

Call on the final hearing is subjective, and has put the governing agencies at tough spot. As we await for the final call, the prevailing situation leaves a lot of room for discussion around what is ideal thing to do.

For more trends follow:

〈Medical Device Trends〉

Your On-line Trend Tracker